Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com For the exclusive use of JATIN CHAWLA at TVF CAPITAL ADVISORS PTE LTD on 19-Jun-2025 20 June 2025 China Pharma and Biotech China Pharma & Biotech: the out-licensing boom, and can it sustain? Growth in China's license deals to the West was one of our major predictions in the 2025 outlook, but the unprecedented momentum shown by recent mega-deals beats even our expectations. Up till June ...

ab 10 June 2025 Powered by YES UBS Evidence Lab Global Research China CRO Sector Biopharma survey: the rising BD, R&D budget and outsourcing rate to benefit CRO/CDMO Wave 2 survey points to rising BD activities and R&D budget UBS Evidence Lab conducted the second wave of the China Biopharma Executive Survey (first wave in 2024), to gauge the biopharma industry's attitude to obtaining further funding, expanding R&D and investment, as well as their willingness to outsource R&D to contract research/development ...